Cocrystal Pharma (NASDAQ:COCP) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Cocrystal Pharma (NASDAQ:COCP) posted its earnings results on Tuesday. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.01, FiscalAI reports.

Cocrystal Pharma Stock Down 2.9%

COCP opened at $1.00 on Tuesday. Cocrystal Pharma has a 12-month low of $0.86 and a 12-month high of $2.67. The firm has a market capitalization of $13.78 million, a P/E ratio of -1.06 and a beta of 1.18. The stock’s 50 day moving average price is $1.02 and its two-hundred day moving average price is $1.07.

Insider Activity

In related news, Director Phillip Md Et Al Frost bought 50,000 shares of the company’s stock in a transaction that occurred on Friday, February 6th. The shares were acquired at an average price of $0.95 per share, with a total value of $47,500.00. Following the completion of the transaction, the director owned 1,888,551 shares of the company’s stock, valued at $1,794,123.45. The trade was a 2.72% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 28.14% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cocrystal Pharma stock. DRW Securities LLC acquired a new stake in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned about 0.24% of Cocrystal Pharma as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 6.72% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cocrystal Pharma in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Cocrystal Pharma has a consensus rating of “Hold” and an average target price of $6.00.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.